Clopidogrel "Resistance": Where are We Now?

Cardiovascular Therapeutics

Volumn 31, Issue 1, 2013, Pages 3-11

  Qureshi, Zeshan ^a   Hobson, Alex R ^b  

^a UNIVERSITY HOSPITAL SOUTHAMPTON NHS FOUNDATION TRUST   (United Kingdom)

^b QUEEN ALEXANDRA HOSPITAL   (United Kingdom)

Author keywords

Coagulation Thrombosis; Interventional cardiology; Ischemic heart disease; Vascular biology

Indexed keywords

CLOPIDOGREL;

ARTICLE; BLEEDING; CLINICAL PRACTICE; DRUG RESISTANCE; GENETIC SCREENING; HIGH RISK PATIENT; HUMAN; LOADING DRUG DOSE; PATIENT COMPLIANCE; PERCUTANEOUS CORONARY INTERVENTION; PRIORITY JOURNAL; STENT; THROMBOCYTE FUNCTION; THROMBOSIS; TREATMENT DURATION; TREATMENT RESPONSE;

DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG RESISTANCE; DRUG SUBSTITUTION; HEMORRHAGE; HUMANS; MEDICATION ADHERENCE; PERCUTANEOUS CORONARY INTERVENTION; PHARMACOGENETICS; PLATELET AGGREGATION; PLATELET AGGREGATION INHIBITORS; PLATELET FUNCTION TESTS; PREDICTIVE VALUE OF TESTS; RISK FACTORS; THROMBOSIS; TICLOPIDINE; TREATMENT FAILURE;

EID: 84872330167     PISSN: 17555914     EISSN: 17555922     Source Type: Journal    
DOI: 10.1111/j.1755-5922.2011.00296.x     Document Type: Article

References (95)

1. Schomig A, Neumann FJ, Kastrati A, et al. A randomized comparison of antiplatelet and anticoagulant therapy after the placement of coronary-artery stents. N Engl J Med 1996;334:1084-1089.
2. Claeys MJ. Antiplatelet therapy for elective coronary stenting: A moving target. Semin Vasc Med 2003;3:415-418.
3. Gori AM, Marcucci R, Migliorini A, et al. Incidence and clinical impact of dual nonresponsiveness to aspirin and clopidogrel in patients with drug-eluting stents. J Am Coll Cardiol 2008;52:734-739.
4. Buonamici P, Marcucci R, Migliorini A, et al. Impact of platelet reactivity after clopidogrel administration on drug-eluting stent thrombosis. J Am Coll Cardiol 2007;49:2312-2317.
5. Hochholzer W, Trenk D, Bestehorn HP, et al. Impact of the degree of peri-interventional platelet inhibition after loading with clopidogrel on early clinical outcome of elective coronary stent placement. J Am Coll Cardiol 2006;48:1742-1750.
6. FDA Drug Safety Communication. Reduced effectiveness of Plavix (clopidogrel) in patients who are poor metabolizers of the drug. Available from: http://www.fda.gov/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/ucm203888.htm [Accessed 8 July 2011].
7. Holmes DR Jr, Dehmer GJ, Kaul S, Leifer D, O'Gara PT, Stein CM. ACCF/AHA clopidogrel clinical alert: Approaches to the FDA "boxed warning": A report of the American College of Cardiology Foundation Task Force on clinical expert consensus documents and the American Heart Association endorsed by the Society for Cardiovascular Angiography and Interventions and the Society of Thoracic Surgeons. J Am Coll Cardiol 2010;56:321-341.
8. Gurbel PA, Tantry US. Clopidogrel resistance?Thromb Res 2007;120;311-321.
9. Hobson AR, Agarwala RA, Swallow RA, Dawkins KD, Curzen NP. Thrombelastography: Current clinical applications and its potential role in interventional cardiology. Platelets 2006;17:509-518.
10. Hobson A, Qureshi Z, Banks P, Curzen N. Effects of clopidogrel on "aspirin specific" pathways of platelet inhibition. Platelets 2009;20:386-390.
11. Hobson AR, Petley GW, Dawkins KD, Curzen N. A novel fifteen minute test for the assessment of individual time dependent clotting responses to aspirin and clopidogrel using modified thrombelastography. Platelets 2007;18:497-505.
12. Muller I, Seyfarth M, Rudiger S, Wolf B, Pogatsa-Murray G, Schomig A, Gawaz M. Effect of a high loading dose of clopidogrel on platelet function in patients undergoing coronary stent placement. Heart 2001;85:92-93.
13. Moussa I, Oetgen M, Roubin G, et al. Effectiveness of clopidogrel and aspirin versus ticlopidine and aspirin in preventing stent thrombosis after coronary stent implantation. Circulation 1999;99:2364-2366.
14. Serebruany VL, Steinhubl SR, Berger PB, Malinin AI, Bhatt DL, Topol EJ. Variability in platelet responsiveness to clopidogrel among 544 individuals. J Am Coll Cardiol 2005;45:246-251.
15. Kushner GF, Hand M, Smith SC, et al. 2009 Focused Updates: ACC/AHA Guidelines for the Management of Patients With ST-Elevation Myocardial Infarction (Updating the 2004 Guideline and 2007 Focused Update) and ACC/AHA/SCAI Guidelines on Percutaneous Coronary Intervention (Updating the 2005 Guideline and 2007 Focused Update): A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol 2009;54:2205-2241.
16. Angiolillo DJ, Fernandez-Ortiz A, Bernardo E, et al. Identification of low responders to a 300-mg clopidogrel loading dose in patients undergoing coronary stenting. Thromb Res 2005;115:101-108.
17. CURE Steering Committee. Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. N Engl J Med 2001;345:494-502.
18. COMMIT Collaborative Group. Addition of clopidogrel to aspirin in 45 852 patients with acute myocardial infarction: Randomised, placebo-controlled trial. Lancet 2005;366:1607-1621.
19. CLARITY-TIMI 28 Investigators. Addition of clopidogrel to aspirin and fibrinolytic therapy for Myocardial infarction with ST-segment elevation. N Engl J Med 2005;352:1179-1189.
20. Mehta SR, Yusuf S, Peters RJ, et al. Effects of pretreatment with clopidogrel and aspirin followed by long-term therapy in patients undergoing percutaneous coronary intervention: The PCI-CURE study. Lancet 2001;358:527-533.
21. Active Steering Committee. Rationale and design of ACTIVE: The atrial fibrillation clopidogrel trial with irbesartan for prevention of vascular events. Am Heart J 2006;151:1187-1193.
22. Wijns W, Kolh P, Danchin N, et al. Guidelines on myocardial revascularization: The Task Force on Myocardial Revascularization of the European Society of Cardiology (ESC) and the European Association for Cardio-Thoracic Surgery (EACTS). Eur Heart J 2010;20:2501-2555.
23. Wenaweser P, Hess O. Stent Thrombosis is associated with an impaired response to anti-platelet therapy. J Am Coll Cardiol 2005;45:1748-1752.
24. Gurbel PA, Bliden KP, Samara W, Yoho JA, Hayes K, Fissha MZ, Tantry US. Clopidogrel effect on platelet reactivity in patients with stent thrombosis: Results of the CREST Study. J Am Coll Cardiol 2005;46:1827-1832.
25. Hobson AR, Petley G, Morton G, Dawkins KD, Curzen NP. Point-of-care platelet function assays demonstrate reduced responsiveness to clopidogrel, but not aspirin, in patients with Drug-Eluting Stent Thrombosis whilst on dual antiplatelet therapy. Thrombs J 2008;6:1.
26. Patti G, Colonna G, Pasceri V, Pepe LL, Montinaro A, Di Sciascio G. Randomized trial of high loading dose of clopidogrel for reduction of periprocedural myocardial infarction in patients undergoing coronary intervention. Circulation 2005;111:2009-2106.
27. Gurbel PA, Bliden KP, Hayes KM, Yoho JA, Herzog WR, Tantry US. The relation of dosing to clopidogrel responsiveness and the incidence of high post treatment platelet aggregation in patients undergoing coronary stenting. J Am Coll Cardiol 2005;45:1392-1396.
28. Angiolillo DJ, Fernandez OA, Bernardo E, et al. High clopidogrel loading dose during coronary stenting: Effect on drug response and interindividual variability. Eur Heart J 2004;25:1903-1910.
29. ALBION Trial Investigators. A randomized comparison of high clopidogrel LDs in patients with non-ST-segment elevation acute coronary syndromes: The ALBION (Assessment of the Best LD of Clopidogrel to Blunt Platelet Activation, Inflammation and Ongoing Necrosis) trial. J Am Coll Cardiol 2006;48:931-938.
30. von Beckerath N, Taubert D, Pogatsa-Murray G, Schömig E, Kastrati A, Schömig A. Absorption, metabolization, and antiplatelet effects of 300-, 600-, and 900-mg LDs of clopidogrel: Results of the ISAR-CHOICE (Intracoronary Stenting and Antithrombotic Regimen: Choose Between 3 High Oral Doses for Immediate Clopidogrel Effect) Trial. Circulation 2005;112:2946-2950.
31. Price MJ, Coleman JL, Steinhubl SR, Wong GB, Cannon CP, Teirstein PS. Onset and offset of platelet inhibition after high-dose clopidogrel loading and standard daily therapy measured by a point-of-care assay in healthy volunteers. Am J Cardiol 2006;98:681-684.
32. Hobson A, Qureshi Z, Banks P, Curzen N. The potential value of near patient platelet function testing in PCI: Randomised comparison of 600 mg versus 900 mg clopidogrel loading doses. Thrombosis 2010. doi:10.1155/2010/908272.
33. Gladding P, Webster M, Zeng I, et al. The antiplatelet effect of higher loading and maintenance dose regimens of clopidogrel the PRINC (Plavix Response in Coronary Intervention) trial. J Am Coll Cardiol Intv 2008;1:612-619.
34. Bonello L, Camoin-Jau L, Arques S, et al. Adjusted clopidogrel loading doses according to vasodilator-stimulated phosphoprotein phosphorylation index decrease rate of major adverse cardiovascular events in patients with clopidogrel resistance: A multicenter randomized prospective study. J Am Coll Cardiol 2008;51:1404-1411.
35. Von Beckerath N, Kastrati A, Wieczorek A, Pogatsa-Murray G, Sibbing D, Graf I, Schomig A. A double blind, randomized study on platelet aggregation in patients treated with a daily dose of 150 mg or 75 mg of clopidogrel for 30 days. Eur Heart J 2007;28:1814-1819.
36. Spretus JA, Kettelkamp R, Vance C, et al. Prevalence, predictors, and outcomes of premature discontinuation of thienopyridine therapy after drug-eluting stent placement: Results from the PREMIER registry. Circulation 2006;113:2803-2809.
37. Iakovou I, Schmidt T, Bonizzoni E, et al. Incidence, predictors, and outcome of thrombosis after successful implantation of drug-eluting stents. JAMA 2005;293:2126-2130.
38. van Werkum JW, Heestermans AA, Zomer AC, et al. Predictors of coronary stent thrombosis: The Dutch Stent Thrombosis Registry. J Am Coll Cardiol 2009;53:1399-1409.
39. Roy P, Bonello L, Torguson R, et al. Temporal relation between clopidodgrel cessation and stent thrombosis after drug-eluting stent implantation. Am J Cardiol 2009;103:801-805.
40. Daemen J, Wenaweser P, Tsuchida K, et al. Early and late coronary stent thrombosis of sirolimus-eluting and paclitaxel-eluting stents in routine clinical practice: Data from a large two-institutional cohort study. Lancet 2007;369:667-678.
41. Samara WM Bliden KP, Tantry US, Gurbel PA. The difference between clopidogrel responsiveness and post treatment platelet reactivity. Thromb Res 2005;115:89-94.
42. Taubert D, von Beckerath N, Grimberg G, et al. Impact of P-glycoprotein on clopidogrel absorption. Clin Pharmacol Ther 2006;80:486-501.
43. Simon T, Verstuyft C, Mary-Krause M, et al. Genetic determinants of response to clopidogrel and cardiovascular events. N Engl J Med. 2009;360:363-375.
44. Gurbel P, Tantry US. Clopidogrel resistance?Thromb Res 2007;120:311-321.
45. Suh JW, Koo BK, Zhang SY, et al. Increased risk of atherothrombotic events associated with cytochrome P450 3A5 polymorphism in patients taking clopidogrel. CMAJ 2006;174:1715-1722.
46. Lau WC, Gurbel PA, Watkins PB, et al. Contribution of hepatic cytochrome P450 3A4 metabolic activity to the phenomenon of clopidogrel resistance. Circulation 2004;109:166-171.
47. Trenk D, Hochholzer W, Fromm MF, et al. Cytochrome P450 2C19 681G>A polymorphism and high on-clopidogrel platelet reactivity associated with adverse 1-year clinical outcome of elective percutaneous coronary intervention with drug-eluting or bare-metal stents. J Am Coll Cardiol 2008;51:1925-1934.
48. Sim SC, Risinger C, Dahl ML, Aklillu E, Christensen M, Bertilsson L, Ingelman-Sundberg M. A common novel CYP2C19 gene variant causes ultrarapid drug metabolism relevant for the drug response to proton pump inhibitors and antidepressants. Clin Pharmacol Ther 2006;79:103-113.
49. Mega JL, Close SL, Wiviott SD, Shen L, Hockett RD, Brandt JT. Cytochrome p-450 polymorphisms and response to clopidogrel. N Engl J Med 2009;360:354-362.
50. Colwell JA, Nair RM, Halushka PV, Rogers C, Whetsell A, Sagel J. Platelet adhesion and aggregation in diabetes mellitus. Metabolism 1979;28:394-400.
51. Fontana P, Dupont A, Gandrille S, Bachelot-Loza C, Reny JL, Aiach M, Gaussem P. Adenosine diphosphate-induced platelet aggregation is associated with P2Y12 gene sequence variations in healthy subjects. Circulation 2003;108:989-995.
52. Angiolillo DJ, Fernandez-Ortiz A, Bernardo E, et al. PIA polymorphism and platelet reactivity following clopidogrel loading dose in patients undergoing coronary stent implantation. Blood Coagul Fibrinolysis 2004;15:89-93.
53. Angiolillo DJ, Fernandez-Ortiz A, Bernardo E, et al. Lack of association between the P2Y12 receptor gene polymorphism and platelet response to clopidogrel in patients with coronary artery disease. Thromb Res 2005;116:491-497.
54. Simon T, Verstuyft C, Mary-Krause M, et al. Genetic determinants of response to clopidogrel and cardiovascular events. N Engl J Med 2009;360:363-375.
55. Cooke GE, Liu-Stratton Y, Ferketich AK, et al. Effect of platelet antigen polymorphism on platelet inhibition by aspirin, clopidogrel, or their combination. J Am Coll Cardiol 2006;47:541-546.
56. Angiolillo DJ, Bernardo E, Ramirez C, et al. Polymorphisms of the GP IIIa and P2Y12 receptors and modulation of antiplatelet effects of combined aspirin and clopidogrel treatment (abstr). Circulation 2004;110:2013.
57. Angiolillo DJ, Fernández-Ortiz A, Bernardo E, et al. 807 C/T polymorphism of the glycoprotein Ia gene and pharmacogenetic modulation of platelet response to dual antiplatelet treatment. Blood Coagul Fibrinolysis 2004;15:427-433.
58. Angiolillo DJ, Fernandez-Ortiz A, Bernardo E, et al. Platelet function profiles in patients with type 2 diabetes and coronary artery disease on combined aspirin and clopidogrel treatment. Diabetes 2005;54:2430-2435.
59. Angiolillo DJ, Bernardo E, Ramirez C, et al. Insulin therapy is associated with platelet dysfunction in patients with type 2 diabetes mellitus on dual oral antiplatelet treatment. J Am Coll Cardiol 2006;48:298-304.
60. Gurbel PA, Bliden KP, Guyer K, et al. Platelet reactivity in patients and recurrent events post-stenting: Results of the PREPARE POST-STENTING Study. J Am Coll Cardiol 2005;46:1820-1826.
61. Tuman KJ, McCarthy RJ, Patel RV, Ivankovich AD. Comparison of thrombelastography and platelet aggregometry. Anesthesiology 1991;75:A433.
62. Lev EI, Patel RT, Maresh KJ, et al. Aspirin and clopidogrel drug response in patients undergoing percutaneous intervention: The role of dual drug resistance. J Am Coll Cardiol 2006;47:27-33.
63. Breet NJ, van Werkum JW, Bouman HJ, et al. Comparison of platelet function tests in predicting clinical outcome in patients undergoing coronary stent implantation. JAMA 2010;303:758-763.
64. Morel O, Viellard C, Faure A, et al. Platelet responsiveness to clopidogrel in patients with coronary syndrome. Comparison of platelet aggregation induced by ADP and flow cytometric analysis of intraplatelet VASP phosphorylation. Ann Cardiol Angeiol 2007;56:21-29.
65. Barragan P, Bouvier JL, Roquebert PO, et al. Resistance to thienopyridines: Clinical detection of coronary Stent Thrombosis by monitoring of Vasodilator-Stimulated Phosphoprotein Phosphorylation. Catheter Cardiovasc Intev 2003;59:295-302.
66. Craft RM, Chavez JJ, Bresee SJ, Wortham DC, Cohen E, Carroll RC. A novel modification of the thrombelastograph assay, isolating platelet function, correlates with optical aggregation. J Lab Clin Med 2004;143:301-309.
67. Gurbel PA, Bliden KP, Guyer K, Aggarwal N, Tantry US. Delayed thrombin-induced platelet-fibrin clot generation by clopidogrel: A new dose-related effect demonstrated by thrombelastography in patients undergoing coronary artery stenting. Thromb Res 2007;119:563-570.
68. Testing Platelet Reactivity In Patients Undergoing Elective Stent Placement on Clopidogrel to Guide Alternative Therapy With Prasugrel (TRIGGER-PCI) Available from: http://clinicaltrials.gov/ct2/show/NCT00910299 [Accessed 18 August 2010].
69. Bonello L, Armero S, Mokhtar OA, et al. Clopidogrel loading dose adjustment according to platelet reactivity monitoring in patients carrying the 2C19 2* loss of function polymorphism. J Am Coll Cardiol 2010;56:1630-1636.
70. CAPRIE Steering Committee. A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). Lancet 1996;348:1329-1339.
71. Bellemain-Appaix A, Brieger D, Beygui F, et al. New P2Y12 inhibitors versus clopidogrel in percutaneous coronary intervention: A meta-analysis. J Am Coll Cardiol 2010;56:1542-1551.
72. Steinhubl SR, Badimon JJ, Bhatt DL, Herbert JM, Lüscher TF. Clinical evidence for anti-inflammatory effects of antiplatelet therapy in patients with atherothrombotic disease. Vasc Med 2007;12:113-122.
73. Tavassoli N, Voisin S, Carrie D, Lapeyre-Mestre M, Galinier M, Montastruc JL, Pathak A. High maintenance dosage of clopidogrel is associated with a reduced risk of stent thrombosis in clopidogrel-resistant patients. Am J Cardiovasc Drugs 2010;10:29-35.
74. Horowitz JD, Rosenson RS, McMurray JJ, Marx N, Remme WJ. Clinical Trials Update AHA Congress 2010. Cardiovasc Drugs Ther 2011;25:69-76.
75. Montalescot G, Sideris G, Cohen R, et al. Prasugrel compared with high-dose Clopidogrel in acute coronary syndrome. The randomized, double-blind ACAPULCO study. Thromb Haemost 2010;103:213-223.
76. Wiviott SD, Braunwald E, McCabe CH, et al. Prasugrel versus clopidogrel in patients with acute coronary syndromes. N Engl J Med 2007;357:2001-2015.
77. Wallentin L, Becker RC, Budaj A, et al. Ticagrelor versus clopidogrel in patients with acute coronary syndromes. N Engl J Med 2009;361:1045-1057.
78. Bhatt DL, Lincoff AM, Gibson CM, et al. Intravenous platelet blockade with cangrelor during PCI. N Engl J Med 2009;361:2330-2341.
79. Bridge Study Maintenance of Platelet Inhibition With Cangrelor (Bridge) Available from: http://clinicaltrials.gov/ct2/show/NCT00767507 [Accessed 18 August 2010].
80. Veno M, Rao SV, Angiolillo DJ. Elinogrel; Pharmacological principles; preclinical and early phase clinical testing. Future Cardiol 2010;6:445-453.
81. Jeong YH, Lee SW, Choi BR, et al. Randomized comparison of adjunctive cilostazol versus high maintenance dose clopidogrel in patients with high post-treatment platelet reactivity: Results of the ACCEL-RESISTANCE (Adjunctive Cilostazol Versus High Maintenance Dose Clopidogrel in Patients With Clopidogrel Resistance) randomized study. J Am Coll Cardiol 2009;53:1101-1109.
82. Cook S, Wenaweser P, Togni M, et al. Incomplete stent apposition and very late stent thrombosis after drug-eluting stent implantation. Circulation 2007;115:2426-2434.
83. Fujii K, Carlier S, Mintz G, et al. Stent underexpansion and residual reference vessel stenosis are associated with stent thrombosis after successful sirlimus-eluting stent implantation. J Am Coll Cardiol 2005;45:995-998.
84. de Jaegere P, Mudra H, Figulla H, et al. Intravascular ultrasound-guided optimized stent deployment. Immediate and 6 months clinical and angiographic results from the Multicenter Ultrasound Stenting in Coronaries Study (MUSIC Study). Eur Heart J 1998;19:1214-1223.
85. Aoki J, Serruys PW, van Beusekom H, et al. Endothelial progenitor cell capture by stents coated with antibody against CD34. J Am Coll Cardiol 2005;45:1574-1579.
86. Price MJ, Berger PB, Angiolillo DJ, et al. Evaluation of individualized clopidogrel therapy after drug-eluting stent implantation in patients with high residual platelet reactivity: Design and rationale of the GRAVITAS trial. Am Heart J 2009;157:818-824.
87. Iijima R, Ndrepepa G, Mehilli J, Bruskina O, Schulz S, Schomig A, Kastrati A. Blood platelet count and 30-day clinical outcomes after percutaneous coronary intervention. Pooled analysis of four ISAR trials. Thromb Haemost 2007;98:852-857.
88. Gurbel PA, Bliden KP, Hiatt BL, O'Connor CM. Clopidogrel for coronary stenting: Response variability, drug resistance, and the effect of pretreatment platelet reactivity. Circulation 2003;107:2908-2913.
89. Angiolillo DJ, Shoemaker SB, Desai B, et al. Antiplatelet Therapy in Diabetes Mellitus (OPTIMUS) Study With Diabetes Mellitus and Coronary Artery Disease: Results of the Optimizing Randomized Comparison of a High Clopidogrel Maintenance Dose in Patients. Circulation 2007;115;708-716.
90. TA182 Acute coronary syndrome - prasugrel: Guidance. Available from: http://guidance.nice.org.uk/TA182/Guidance/pdf/English [Accessed 24 August 2010].
91. Rao SV, O'Grady K, Pieper KS, et al. Impact of bleeding severity on clinical outcome among patients with acute coronary syndromes. Am J Cardiol 2005;96:1200-1206.
92. Feit F, Voeltz MD, Attubato MJ, et al. Predictors and impact of major haemorrhage on mortality following percutaneous coronary intervention from the REPLACE-2 trial. Am J Cardiol 2007;100:1364-1369.
93. Thrombocyte Activity Reassessment and GEnoTyping for PCI (TARGET-PCI). Available from: http://www.clinicaltrials.gov/ct2/show/NCT01177592?term=TARGETPCI&rank=1 [Accessed 15 March 2011].
94. A Comparison of Prasugrel and Clopidogrel in Acute Coronary Syndrome Subjects (TRILOGY ACS). Available from: http://clinicaltrials.gov/ct2/show/NCT00699998 [Accessed 23 March 2011].
95. Prevention of Cardiovascular Events (eg, Death From Heart or Vascular Disease, Heart Attack, or Stroke) in Patients With Prior Heart Attack Using Ticagrelor Compared to Placebo on a Background of Aspirin (PEGASUS) Available from: http://clinicaltrials.gov/ct2/show/NCT01225562?term=PEGASUS&rank=1 [Accessed 23 March 2011].